The acquisition is expected to augment Indegene’s commercialization portfolio spanning drug discovery and development to marketing and sales, adding brand strategy and market development capabilities along with patient engagement platforms. The Bengaluru-based Indegene with sales of $223 million in FY22, is the fastest growing digital company offering services to life sciences.
